Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062555 · ClinicalTrials.gov registry record · Phase 1
Calcineurin Inhibitor Sparing After Kidney Transplantation
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 527
- Enrollment target
NCT01062555: Completed Phase 1 study, sponsored by University of Minnesota.
NCT01062555 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 527 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (778% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01062555, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 527 participants
- Enrollment target
Study Summary
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant function in those who have had their transplants for many years. The introduction of new immunosuppression medications however, has provided the opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the kidney.
Primary Outcome
The percentage of patients alive at 6 month post transplant.
Interventions
- DRUG Cyclosporine & Cellcept
- DRUG Prograf & Cellcept
- DRUG Low Dose CNI (Cyclosporine or FK) and Cellcept
- DRUG Rapamune and Cellcept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2006-10-01 |
| Est. Completion | 2014-04-03 |
| Phase | Phase 1 |
What the finished NCT01062555 record still lists
NCT01062555 is an interventional study that assigns participants to a tested intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (778% higher).
The record links to 0 conditions, and to 4 interventions - of which Cyclosporine & Cellcept is the first listed.
NCT01062555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01062555 about?
NCT01062555 is a clinical study titled "Calcineurin Inhibitor Sparing After Kidney Transplantation". Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant fu...
What is the current status of trial NCT01062555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 527 participants. The study started on 2006-10-01. Estimated completion is 2014-04-03.
What interventions are being tested in trial NCT01062555?
The interventions under investigation include: Cyclosporine & Cellcept (DRUG), Prograf & Cellcept (DRUG), Low Dose CNI (Cyclosporine or FK) and Cellcept (DRUG), Rapamune and Cellcept (DRUG).
Who is sponsoring clinical trial NCT01062555?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01062555's enrollment target sits among peer trials
527 39th of 2000 higher than 1,962 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI